Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.
Press releases published on April 16, 2025
DIAGNOS annonce des avancées majeures dans sa certification de Cybersécurité par le Centre opérationnel de cyberdéfense (COCD) pour son application CARA System
GlobeNewswire
·
April 16, 2025
BROSSARD, Québec, 16 avr. 2025 (GLOBE NEWSWIRE) -- Diagnos inc. (« DIAGNOS » ou la « Société ») (Bourse de croissance TSX : ADK, OTCQB : DGNOF, FWB : 4D4A), un pionnier de la détection précoce de certains problèmes de santé ophtalmique à l'aide d'une …
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME
GlobeNewswire
·
April 16, 2025
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME ISTURISA® is a cortisol synthesis inhibitor that blocks the enzyme 11β-hydroxylase to help normalize …
Prime Biome (Updated 2025): A Comprehensive Review of the Groundbreaking Skin-Gut Axis Supplement
GlobeNewswire
·
April 16, 2025
ST. PETERSBURG, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- Prime Biome is a revolutionary gut-skin health supplement that has taken center stage in holistic wellness. This probiotic formula promises simultaneous benefits for skin radiance and digestive …
Conditional Issuance of Shares
GlobeNewswire
·
April 16, 2025
INSIDE INFORMATION REGULATED INFORMATION Conditional Issuance of Shares Mont-Saint-Guibert, Belgium – April 16, 2025, 8:00 am CET / 2:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), today announced a conditional issuance …
Émission Conditionnelle d’Actions
GlobeNewswire
·
April 16, 2025
INFORMATIONS PRIVILÉGIÉES INFORMATIONS RÉGLEMENTÉES Émission Conditionnelle d’Actions Mont-Saint-Guibert, Belgique – le 16 avril 2025, 8:00h CET / 2:00h ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” ou la “Société”), a annoncé aujourd’hui une …
Basilea berichtet über Präsentation neuer Daten zu Fosmanogepix, Isavuconazol (Cresemba®) und Ceftobiprol (Zevtera®) auf dem Fachkongress ESCMID Global 2025
GlobeNewswire
·
April 16, 2025
Allschwil, 16. April 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, gab …
Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025
GlobeNewswire
·
April 16, 2025
Allschwil, Switzerland, April 16, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today scientific …
Santhera informiert über den kommerziellen Rollout von AGAMREE®
GlobeNewswire
·
April 16, 2025
Pratteln, Schweiz, 16. April 2025 - Santhera Pharmaceuticals (SIX: SANN) gibt den neuesten Fortschritt beim kommerziellen Rollout von AGAMREE® zur Behandlung von Duchenne-Muskeldystrophie (DMD) bekannt. Für AGAMREE zur Behandlung von Duchenne- …
Santhera shares updates on commercial rollout of AGAMREE®
GlobeNewswire
·
April 16, 2025
Pratteln, Switzerland, April 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the latest progress on the commercial rollout of AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD). Funding from National Health Service (NHS) England is …
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
GlobeNewswire
·
April 16, 2025
Total sales growth of 11.6% at CER1, or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay. Tovorafenib regulatory submission to EMA2 for pediatric low-grade glioma. Confirmation of full …
Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l’exercice 2025
GlobeNewswire
·
April 16, 2025
Croissance des ventes de 11,6% à taux de change constant1, ou 11,7% en données publiées, tirée par toutes les aires thérapeutiques, incluant une contribution croissante d'Iqirvo et de Bylvay. Soumission réglementaire à l'EMA2 de tovorafenib pour le gliome …
Automated Health Systems Expands Access to Public Healthcare Nationwide with Smarter Solutions
GlobeNewswire
·
April 16, 2025
Dr. Moses Haregewoyn leads Automated Health Systems, which uses technology and structured management to expand access to public healthcare for individuals, providers, and agencies. The company has grown steadily by supporting programs that connect more …